Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years
the ONA take:
An analysis of data from the Surveillance, Epidemiology, and End Results–Medicare database has found that sunitinib and sorafenib may be associated with an increased risk of cardiovascular events, particularly stroke, in older patients with renal cell carcinoma (RCC).
Sorafenib and sunitinib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for the treatment of RCC.
The population-based, observational cohort study analyzed patients ages 66 years or older with RCC diagnosed between 2000 and 2009. The researchers examined incidence of cardiovascular events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths through December 2010.
Of the 670 patients who received sorafenib or sunitinib, 171 had experienced a cardiovascular event. Use of either of the drugs was associated with an increased risk of cardiovascular events and especially stroke compared with 788 patients with advanced RCC diagnosed from 2007 to 2009 who did not receive either agent.
Subgroup analyses revealed that patients ages 66 to 74 years at diagnosis had the highest increased risk of stroke associated with use of sorafenib or sunitinib, or both.
Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|